A cancer treatment program that an ASC might consider implementing and adding to the services it offers is that of brachytherapy to treat prostate cancer.
Dallas, Texas, September 09, 2014 – A cancer treatment program that an ASC might consider implementing and adding to the services it offers is that of brachytherapy to treat prostate cancer. There are many ways in which a brachytherapy program can prove beneficial and profitable for an ASC.
In an article published by The Ambulatory M&A Advisor, the benefits of Low Dose Rate brachytherapy to both the ASC and the patient are explained.
Brachytherapy is performed by a urologist and a radiation oncologist and is an outpatient procedure that can be done in as little as one hour. Low Dose Rate Brachytherapy involves the placing of a “seed” of radioactive material directly inside the tumor.
One of the major benefits of brachytherapy is that it allows the doctor to better control the radiation and decrease impact on healthy tissues.
“Prostate brachytherapy requires a urologist, radiation oncologist, an anesthesiologist for day of procedure as well as a medical dosimetrist or physicist for treatment planning,” said Chief Executive Officer of Prologics Healthcare, LLC, Roger Corle. “Typically ASCs with urology participation or ownership are ideal candidates for starting a prostate brachytherapy program.”
Furthermore, the equipment and licensures needed to implement a prostate brachytherapy program in an ASC are not as expensive as one might initially assume.
To read the article in full, click here.
The Ambulatory M&A Advisor is an online publication that covers the most up-to-date trends and topics surrounding ambulatory care center deal making, including information on investment banking in the ambulatory care sector.
Blayne Rush, MHP, MBA
Ambulatory Alliances, LLC
18181 Midway Rd Ste 200
Dallas, Texas 75287